Cardinal Health Inc.
CAH evidence brief
What we can confirm
- BioSniper Score:
- 3.5 / 10
- Market Cap:
- $55.83B
- Lead Asset:
- sodium iodide i 131 (Approved)
What it means
What to watch
Prepared research question
What matters most for CAH—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CAH
Cardinal Health Inc. (CAH) is a healthcare services company operating through Pharmaceutical and Specialty Solutions, Global Medical Products and Distribution, and other segments including Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight Logistics.
Key risk: Negative shareholders' equity
BioSniper Score
Based on 5 of 6 signals
Market Cap
$55.83B
Cash Runway
—
Lead Asset
sodium iodide i 131 (Approved)
Next Catalyst
Patent_Expiry · Jan 30, 2029Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 1 clinical trial · 1 catalyst · 2 FDA decisions for Cardinal Health Inc..
Cardinal Health Inc. (CAH) is a healthcare services company operating through Pharmaceutical and Specialty Solutions, Global Medical Products and Distribution, and other segments including Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight Logistics.
- Cash & equivalents of $4,856.0M as of 2026-06-30 [sec].
- Shareholders' equity of -$2,883.0M as of 2026-06-30 [sec].
- Fiscal 2026 marked strong execution against strategic priorities, including expansion of specialty care offerings and patient access support [sec · filed 2026-09-21].
- Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight Logistics benefited from favorable healthcare trends and targeted investments [sec · filed 2026-09-21].
- Cardinal Health is expanding Ac-225 production capacity to support radiopharmaceutical cancer therapies [news · published 2026-04-02].
What works
- The company's Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight Logistics businesses 'continued to benefit from favorable healthcare trends, strong customer demand, and targeted investments in technology, automation, and capacity expansion' [sec · filed 2026-09-21].
- Cardinal Health is expanding Ac-225 capacity to support growing demand for radiopharmaceutical cancer therapies, positioning itself in a high-growth area [news · published 2026-04-02].
- The company strengthened its position as a strategic partner to specialty providers and biopharmaceutical manufacturers through expanded patient access and support offerings [sec · filed 2026-09-21].
What to weigh
- Shareholders' equity is negative at -$2,883.0M as of 2026-06-30, indicating accumulated losses exceed equity [sec].
- The company's reportable segments exclude three operating segments (Nuclear and Precision Health Solutions, at-Home Solutions, OptiFreight Logistics) because they are 'not significant enough financially to require separate reportable segment disclosures' [sec · filed 2026-09-21].
- A patent expiry for TECHNETIUM TC-99M TILMANOCEPT is scheduled for 2029-01-30, which could affect a product in the Nuclear and Precision Health Solutions segment [catalyst].
From the filings
Quoted directly from source documents.
Expansion of Ac-225 capacity for radiopharmaceutical cancer therapies
“Cardinal Health Expands Ac-225 Capacity to Boost Cancer Therapies”
News · April 2, 2026
Fiscal 2026 execution against strategic priorities
“Fiscal 2026 marked another year of strong execution against Cardinal Health's strategic priorities.”
SEC filings · September 21, 2026
Catalyst timeline
- 2029-01-30 · Patent_Expiry · TECHNETIUM TC-99M TILMANOCEPT — Patent_Expiry: NDA202207 — Patent expiry for a radiopharmaceutical product; may affect competitive positioning in Nuclear and Precision Health Solutions.
Risks & what to watch (3)›
Key risks
- Negative shareholders' equity — Shareholders' equity is -$2,883.0M as of 2026-06-30, indicating a structural deficit [sec].
- Patent expiry for radiopharmaceutical — Patent expiry for TECHNETIUM TC-99M TILMANOCEPT on 2029-01-30 may affect Nuclear and Precision Health Solutions [catalyst].
- Small non-reportable segments — Three operating segments are not financially significant enough for separate disclosure, limiting visibility [sec · filed 2026-09-21].
What to watch
- Patent expiry of TECHNETIUM TC-99M TILMANOCEPT on 2029-01-30 and its impact on the Nuclear and Precision Health Solutions segment [catalyst].
- Continued expansion of Ac-225 production capacity and its role in radiopharmaceutical cancer therapy commercialization [news · published 2026-04-02].
- Performance of the three non-reportable segments (Nuclear and Precision Health Solutions, at-Home Solutions, OptiFreight Logistics) as they grow [sec · filed 2026-09-21].
- Ability to improve shareholders' equity from its negative position of -$2,883.0M as of 2026-06-30 [sec].
Sources: Competitor trials · News · SEC filings · Generated October 11, 2026 · How we verify sources →
Run Cardinal Health Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Cardinal Health Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
Cash runway data unavailable
N/A
Lead: Approved
1 candidate
1 upcoming, next in ~839d
0 buys · 31 sells (180d)
Catalysts
Pipeline
Regulatory
Financials
Short Interest
as of May 20, 2026- % of float
- 3.0%
- Days to cover
- 3.7
- Shares short
- 6,063,099
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CAH short interestGovernance
Frequently asked questions
What is the AI investment thesis for Cardinal Health Inc.?
Cardinal Health Inc. (CAH) is a healthcare services company operating through Pharmaceutical and Specialty Solutions, Global Medical Products and Distribution, and other segments including Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight Logistics.
What is Cardinal Health Inc.'s lead drug candidate?
Cardinal Health Inc.'s most advanced tracked candidate is sodium iodide i 131 (Approved).
What is Cardinal Health Inc.'s next catalyst?
Cardinal Health Inc.'s next tracked catalyst is a Patent_Expiry event — "Patent_Expiry: NDA202207" — expected January 30, 2029.
Who is the CEO of Cardinal Health Inc.?
Mr. Jason M. Hollar is the chief executive officer of Cardinal Health Inc. (CAH).
Where is Cardinal Health Inc. headquartered?
Cardinal Health Inc. (CAH) is headquartered in Dublin, OH, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.